Your session is about to expire
← Back to Search
Personalized Cancer Treatment Intensity for Oropharyngeal Cancer
Study Summary
This trial is testing whether a person's genes can predict how well they'll respond to a less intense cancer treatment plan.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My recent blood tests show enough platelets and hemoglobin.My cancer is in the oropharynx and hasn't spread far.I can follow the treatment and check-up schedule.My cancer cannot be removed with surgery.My recent scans showed no cancer spread through blood.My kidney and liver tests are within normal limits.I am currently on medication for rheumatoid arthritis.I am HIV positive.My cancer is squamous cell and tests positive for HPV or p16.I have had radiation therapy to my head or neck before.I have had head or neck cancer in the past.I am 18 years old or older.I am fully active or can carry out light work.
- Group 1: ≤ 10 pack years smoking history
- Group 2: > 10 py smoking history, no p53 mutation
- Group 3: > 10 py smoking history, p53 mutation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are some of the risks associated with Intensity Modulated Radiotherapy (IMRT) - deintensified?
"Intensity Modulated Radiotherapy (IMRT) - deintensified is currently in Phase 2 of clinical trials. While there is supportive data for safety, there remains a lack of evidence regarding efficacy. Our team has rated it as a 2 on our 3-point scale."
Could you please explain what Intensity Modulated Radiotherapy (IMRT) - deintensified is typically used for?
"While most commonly used to treat advanced ovarian cancer, Intensity Modulated Radiotherapy (IMRT) - deintensified can also be used as a last resort for patients with refractory testicular cancer and advance directives."
Are there any current vacancies for this experiment?
"Unfortunately, this trial is not currently enrolling patients. Although, it's worth noting that the study was last updated on January 25th, 2022. There are 5257 trials actively seeking cancer of oropharnyx participants and 714 for Intensity Modulated Radiotherapy (IMRT) - deintensified if you're looking for other options."
How many different medical clinics are participating in this study?
"The trial is being conducted at 4 sites. 3 of the locations are in North carolina (Gainesville, Chapel Hill and Raleigh) with 1 other site in an undisclosed location. If you enroll, choose the nearest option to limit travel."
Can you please provide context for this IMRT - deintensified clinical trial in relation to other similar trials?
"At this time, there are 714 ongoing clinical trials investigating Intensity Modulated Radiotherapy (IMRT) - deintensified. Of these trials, 284 are in Phase 3. Many of the clinical trials for Intensity Modulated Radiotherapy (IMRT) - deintensified are based in Shanghai, but there are 43259 locations operating studies for Intensity Modulated Radiotherapy (IMRT) - deintensified worldwide."
Share this study with friends
Copy Link
Messenger